Haematology and Leukaemia

Entry requirements

For full entry requirement details, please see the course page on the University website.

Months of entry

Anytime

Course content

Our commitment to cancer research has resulted in the launch of Liverpool Cancer Research UK Centre – an organisation that brings together scientists, clinicians and local stakeholders to lead and deliver cancer research of the highest quality and importance.

Haemato-oncology is one of Liverpool’s recognised strengths with scientific expertise in Chronic Myeloid Leukemia (CML) and lymphoproliferative disorders and strong clinical leadership that includes chairmanship of the National Cancer Research Institute (NCRI) Haematological Oncology CSG and CML Subgroup and membership of the Lymphoma CSG and Subgroups for Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), High Grade Non-Hodgkin's Lymphomas (HG-NHL) and Low Grade Non-Hodgkin's Lymphomas (LG-NHL).

Professor Andrew Pettitt leads a large programme of clinical and translational research focussed on lymphoid malignancy with strong links with industry and national collaborative groups in lymphoma and haematological oncology.

Our research interests

• Clinical studies conducted with the intent to advance therapies to the clinic or develop principles for application of therapeutics to human disease
• Non-human or non-clinical studies conducted with the intent to advance therapies to the clinic or develop principles for application of therapeutics to human disease
• Investigations in humans which define the biology of disease and provide the scientific foundation for the development of new or improved therapies for human disease
• Any clinical trial of a therapy that was initiated based on the above.